Replies to post #27922 on Curative Biotechnology Inc (CUBT)

[Mooseface]

For the OTC, 300 mil is low. They will not need to R/S to uplist. The Priority Review Voucher for the symptomatic rabies treatment is alone worth $125-200 million, now couple that with the new patent they just acquired and whatever other irons they have in the fire, a $300 million market cap will not be hard to achieve for this company.